Therapies are selected based on the biological characteristics of the tumor, namely subtypes classified by the expression of estrogen receptor alpha (ER), progesterone receptor (PR), and amplification of the gene encoding the human epidermal growth factor receptor 2 (HER2) [3–6]. The gene discussed is ESR1; the disease is neoplasm.